Press release
Vascular Malformations Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Discover the latest drugs and treatment options in the Vascular Malformations Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight [https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Vascular Malformations Pipeline Report
* On February 05, 2026, Alnylam Pharmaceuticals initiated a phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and multiple-dose ALN-6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT).
* In January 2026, Relay Therapeutics Inc . announced a Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3K inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
* DelveInsight's Vascular Malformations Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Vascular Malformations treatment.
* The leading Vascular Malformations Companies such as Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.
* Promising Vascular Malformations Pipeline Therapies such as Everolimus, Alpelisib, Cobimetinib, CYH33, RLY-2608, PTX-022, TARA-002, Ticagrelor, Alpelisib (BYL719), SRM003 , and others.
Stay ahead with the most recent pipeline outlook for Vascular Malformations. Get insights into clinical trials, emerging therapies, and leading companies with Vascular Malformations @ Vascular Malformations Treatment Drugs [https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Vascular Malformations Emerging Drugs Profile
* VT 30: Venthera
VT 30, is a novel investigational therapy is designed to target the genetic drivers of venous (VM), lymphatic (LM), and venolymphatic malformations (VLM) at their source by delivering a potent PI3K inhibitor directly to affected tissue. The majority of these cutaneous vascular malformations are driven by somatic mutations in the PIK3CA and TEK genes. These mutations result in overactivation of the PI3K pathway and have been identified as the root cause of the vast majority of VMs, LMs, and VLMs. Because BBP-681 is applied directly to skin lesions, it may minimize complications seen with systemic treatments.
* NPC-12: Nobelpharma
NPC-12, is an investigational drug being developed by Nobelpharma.It is acts as a T lymphocyte inhibitor. Currently, the drug is being evaluated at Phase III for the treatment of vascular anomalies.
The Vascular Malformations Pipeline Report Provides Insights into-
* The report provides detailed insights about companies that are developing therapies for the treatment of Vascular Malformations with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vascular Malformations Treatment.
* Vascular Malformations Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Vascular Malformations Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vascular Malformations market
Explore groundbreaking therapies and clinical trials in the Vascular Malformations Pipeline. Access DelveInsight's detailed report now! @ New Vascular Malformation Drugs [https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Vascular Malformations Companies
Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.
Vascular Malformations pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Vascular Malformations Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Vascular Malformations Treatment. Learn about new drugs, Vascular Malformations Pipeline developments, and key companies with DelveInsight's expert analysis @ Vascular Malformations Market Drivers and Barriers [https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Vascular Malformations Pipeline Report
* Coverage- Global
* Vascular Malformations Companies- Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.
* Vascular Malformations Pipeline Therapies- Everolimus, Alpelisib, Cobimetinib, CYH33, RLY-2608, PTX-022, TARA-002, Ticagrelor, Alpelisib (BYL719), SRM003 , and others.
* Vascular Malformations Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Vascular Malformations Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Vascular Malformations Pipeline Therapies and clinical trials. Download DelveInsight's in-depth Pipeline Report today! @ Vascular Malformations Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/vascular-malformations-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Vascular Malformations: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Vascular Malformations- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NPC-12: Nobelpharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* VT 30: Venthera
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Vascular Malformations Key Companies
* Vascular Malformations Key Products
* Vascular Malformations- Unmet Needs
* Vascular Malformations- Market Drivers and Barriers
* Vascular Malformations- Future Perspectives and Conclusion
* Vascular Malformations Analyst Views
* Vascular Malformations Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vascular-malformations-clinical-trial-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/vascular-malformations-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vascular Malformations Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight here
News-ID: 4398136 • Views: …
More Releases from ABNewswire
Oncolytic Virus Cancer Therapy Clinical Trial Pipeline Appears Robust With 120+ …
DelveInsight's, "Oncolytic Virus Cancer Therapy Pipeline Insight 2026" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
The Meeting Reset: How Dee Agarwal Recommends Streamlining Collaboration
Dee Agarwal shares a practical reset for modern meetings, showing leaders how to cut unnecessary calls, right-size participation, and make collaboration purposeful, focused, and outcome-driven.
ATLANTA, GA - February 19th, 2026 - Meetings were once the backbone of collaboration. Somewhere along the way, they became a source of frustration. Calendars filled up, agendas blurred, and outcomes grew harder to pinpoint. According to meeting research cited by Flowtrace, Harvard Business Review reports…
ERA-co Appoints Global Workplace Expert Stav Eilam as Strategy Director, Strengt …
LONDON, UK - Global placemaking and urban strategy consultancy ERA-co [https://era-co.com/] appointment of Stav Eilam as Strategy Director in its London studio, further strengthening the firm's workplace and strategic advisory capability across the UK and European markets.
"As global investor confidence returns to the UK office market, we see a significant opportunity to expand our strategic advisory capability," said Amanda Stanaway, Global Head of User Strategy at ERA-co. "Stav brings deep…
A Furry Messenger of Hope: F.K. Smith's New Children's Book Explores Faith, Fami …
F.K. Smith's new children's book, Polar Bear, Solar Bear [https://www.amazon.com/POLAR-BEAR-SOLAR-F-SMITH/dp/1105825957/ref=sr_1_1?crid=1CY1GG93AEFS1&dib=eyJ2IjoiMSJ9.32AYPesBUgoP9rOCumkkK3jGnDaJ_haqVyGTPe0sKiw.cVqaAIsbDpGX2kqTyyYxmSB4aRNA9BZ1isgiEK3jDYg&dib_tag=se&keywords=polar+bear+solar+bear+fk+smith&qid=1770840463&sprefix=polar+bear+solar+bear%2Caps%2C397&sr=8-1], tells a heartwarming story about love and faith through the journey of a small polar bear who searches for her true home. The book presents a safe, familiar world that teaches children through gentle lessons.
The story of Solar Bear [https://www.amazon.com/POLAR-BEAR-SOLAR-F-SMITH/dp/1105825957/ref=sr_1_1?crid=1CY1GG93AEFS1&dib=eyJ2IjoiMSJ9.32AYPesBUgoP9rOCumkkK3jGnDaJ_haqVyGTPe0sKiw.cVqaAIsbDpGX2kqTyyYxmSB4aRNA9BZ1isgiEK3jDYg&dib_tag=se&keywords=polar+bear+solar+bear+fk+smith&qid=1770840463&sprefix=polar+bear+solar+bear%2Caps%2C397&sr=8-1]starts in Alaska's frozen territory, where a polar bear mother makes her toughest decision to protect her cub from death. The…
More Releases for Vascular
High Prevalence Of Vascular Diseases Drives Global Vascular Grafts Market: An Em …
The Vascular Grafts Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Vascular Grafts Market?
In recent years, there has been consistent growth in the size of the vascular grafts market. The market is projected to expand from $3.25 billion…
Vascular Disease Surge Fuels Anticipated Growth In The Vascular Embolization Mar …
The Vascular Embolization Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Vascular Embolization Market Size and Its Estimated Growth Rate?
The growth of the vascular embolization market has been robust in recent times, escalating from $3.15 billion in 2024 to an estimated…
Vascular Embolization Market - Empowering Vascular Wellness through Embolization
Newark, New Castle, USA: The "Vascular Embolization Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Vascular Embolization Market: https://www.growthplusreports.com/report/vascular-embolization-market/8433
This latest report researches the industry structure, sales, revenue,…
Large Bore Vascular Closure Devices Market Is Booming Worldwide | Abbott Vascula …
The Large Bore Vascular Closure Devices Market report provides the overall structure and business outlook of the global and regional industries. The study also involves the important Achievements of the market, Research & Development, new product launch, product responses, and regional growth of the leading competitors operating in the market on a global and local scale. This study provides information about the growth and revenue during the historic and forecasted…
Vascular Stent Market - Opportunities Outlook & Key Players 2025 | Vascular Conc …
Global Vascular Stent Market: Snapshot
The global market for vascular stents has been growing at a robust rate on account of the rising incidence of cardiovascular diseases across the globe. The healthcare industry has been witnessing an overbearing amount of patients who have suffered heart strokes or cardiac arrests. This has paved way for increased demand within the global market for vascular stents. These stents can be useful during angioplasty and…
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations.
Request for Sample of This Research Report @ https://bit.ly/2xjOKpC
Top Key Player:-
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
R. Brad, Inc.
Cardinal Health, Inc.
Medtronic plc.
Cook Medical, Inc.
Teruma Corporation
Jude Medical, Inc.
The Spectranetics Corporation
Volcano Corporation
Peripheral vascular disorder (PVD) is a blood circulation disorder…
